Cargando…

Nalbuphine versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section

BACKGROUND AND PURPOSE: Adding adjuvants to intrathecal hyperbaric bupivacaine provides long analgesic duration with less adverse effects. The aim of this study was to compare intrathecal nalbuphine versus midazolam in patients undergoing cesarean section. CLINICAL TRIAL ID: NCT03918187. PATIENTS AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Olfat Abdelmoniem Ibrahem, Ibrahem, Mohamed Abdel-moniem, Salem, Dina Abdelhameed Elsadek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295533/
https://www.ncbi.nlm.nih.gov/pubmed/32606903
http://dx.doi.org/10.2147/JPR.S242545
_version_ 1783546667445780480
author Amin, Olfat Abdelmoniem Ibrahem
Ibrahem, Mohamed Abdel-moniem
Salem, Dina Abdelhameed Elsadek
author_facet Amin, Olfat Abdelmoniem Ibrahem
Ibrahem, Mohamed Abdel-moniem
Salem, Dina Abdelhameed Elsadek
author_sort Amin, Olfat Abdelmoniem Ibrahem
collection PubMed
description BACKGROUND AND PURPOSE: Adding adjuvants to intrathecal hyperbaric bupivacaine provides long analgesic duration with less adverse effects. The aim of this study was to compare intrathecal nalbuphine versus midazolam in patients undergoing cesarean section. CLINICAL TRIAL ID: NCT03918187. PATIENTS AND METHODS: This was a prospective randomized controlled study conducted on 90 females undergoing cesarean section under spinal anesthesia who were randomly allocated to three equal groups of 30 patients each: group C received hyperbaric bupivacaine 12.5 mg plus 0.5 mL saline, group N received hyperbaric bupivacaine 12.5 mg plus 1 mg nalbuphine, group M received hyperbaric bupivacaine 12.5 mg plus 2.5 mg midazolam. The onset and duration of sensory and motor block, effective analgesic time, analgesic requirements, adverse effects, sedation, and Apgar scores were recorded. RESULTS: There was significant rapid onset of sensory and motor block (1.95±.44 and 3.50±0.43 min) with slower regression of sensory block and time to bromage I (211.6±13.2 and 219.8±20.2 min) in group N compared to groups M, C (p < 0.001), with statistically significant rapid onset and long duration of both blocks in group M compared to C (p<0.001). The effective analgesic time was significantly prolonged in group N (263.7±16.3) compared to groups M and C (224.2 ± 18.6, 185.5±17.45), respectively, (p<0.001) and prolonged in group M compared to C (p<0.001), with increase in analgesic requirement in group C compared to groups N and M (p<0.001) and no significant difference between groups N and M. There was higher sedation score in groups N, M (1.78±0.63, 2.75±0.54), respectively, compared to group C (0.61±0.12) (p<0.001) with lower Apgar score in group M (6.9±0.73) at one minute than in groups N, C (7.1±0.91, 7.7±0.84) (p<0.001). There was no significant difference between groups regarding the adverse effects. CONCLUSION: Adding 1 mg nalbuphine to 12.5 mg hyperbaric bupivacaine provided more effective postoperative analgesia than adding 2.5 mg midazolam, with less non-significant adverse effects in midazolam group in patients undergoing elective cesarean section.
format Online
Article
Text
id pubmed-7295533
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72955332020-06-29 Nalbuphine versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section Amin, Olfat Abdelmoniem Ibrahem Ibrahem, Mohamed Abdel-moniem Salem, Dina Abdelhameed Elsadek J Pain Res Original Research BACKGROUND AND PURPOSE: Adding adjuvants to intrathecal hyperbaric bupivacaine provides long analgesic duration with less adverse effects. The aim of this study was to compare intrathecal nalbuphine versus midazolam in patients undergoing cesarean section. CLINICAL TRIAL ID: NCT03918187. PATIENTS AND METHODS: This was a prospective randomized controlled study conducted on 90 females undergoing cesarean section under spinal anesthesia who were randomly allocated to three equal groups of 30 patients each: group C received hyperbaric bupivacaine 12.5 mg plus 0.5 mL saline, group N received hyperbaric bupivacaine 12.5 mg plus 1 mg nalbuphine, group M received hyperbaric bupivacaine 12.5 mg plus 2.5 mg midazolam. The onset and duration of sensory and motor block, effective analgesic time, analgesic requirements, adverse effects, sedation, and Apgar scores were recorded. RESULTS: There was significant rapid onset of sensory and motor block (1.95±.44 and 3.50±0.43 min) with slower regression of sensory block and time to bromage I (211.6±13.2 and 219.8±20.2 min) in group N compared to groups M, C (p < 0.001), with statistically significant rapid onset and long duration of both blocks in group M compared to C (p<0.001). The effective analgesic time was significantly prolonged in group N (263.7±16.3) compared to groups M and C (224.2 ± 18.6, 185.5±17.45), respectively, (p<0.001) and prolonged in group M compared to C (p<0.001), with increase in analgesic requirement in group C compared to groups N and M (p<0.001) and no significant difference between groups N and M. There was higher sedation score in groups N, M (1.78±0.63, 2.75±0.54), respectively, compared to group C (0.61±0.12) (p<0.001) with lower Apgar score in group M (6.9±0.73) at one minute than in groups N, C (7.1±0.91, 7.7±0.84) (p<0.001). There was no significant difference between groups regarding the adverse effects. CONCLUSION: Adding 1 mg nalbuphine to 12.5 mg hyperbaric bupivacaine provided more effective postoperative analgesia than adding 2.5 mg midazolam, with less non-significant adverse effects in midazolam group in patients undergoing elective cesarean section. Dove 2020-06-11 /pmc/articles/PMC7295533/ /pubmed/32606903 http://dx.doi.org/10.2147/JPR.S242545 Text en © 2020 Amin et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Amin, Olfat Abdelmoniem Ibrahem
Ibrahem, Mohamed Abdel-moniem
Salem, Dina Abdelhameed Elsadek
Nalbuphine versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section
title Nalbuphine versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section
title_full Nalbuphine versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section
title_fullStr Nalbuphine versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section
title_full_unstemmed Nalbuphine versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section
title_short Nalbuphine versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section
title_sort nalbuphine versus midazolam as an adjuvant to intrathecal bupivacaine for postoperative analgesia in patients undergoing cesarean section
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295533/
https://www.ncbi.nlm.nih.gov/pubmed/32606903
http://dx.doi.org/10.2147/JPR.S242545
work_keys_str_mv AT aminolfatabdelmoniemibrahem nalbuphineversusmidazolamasanadjuvanttointrathecalbupivacaineforpostoperativeanalgesiainpatientsundergoingcesareansection
AT ibrahemmohamedabdelmoniem nalbuphineversusmidazolamasanadjuvanttointrathecalbupivacaineforpostoperativeanalgesiainpatientsundergoingcesareansection
AT salemdinaabdelhameedelsadek nalbuphineversusmidazolamasanadjuvanttointrathecalbupivacaineforpostoperativeanalgesiainpatientsundergoingcesareansection